There is momentum for Glenmark’s Ryaltris across new launch markets internationally, with FY2023 and FY2024 seen as important years for revenue scale-up. A partnered nitric oxide nasal spray for COVID-19 faces trial recruitment challenges in India but the firm hopes to be able to debut the product this year.

From the latest COVID-19 advances to the emergence of a game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.

ENA Respiratory expects its "preventive" nasal spray, which primes innate immunity against respiratory viruses including SARS-CoV-2, to play a meaningful role in protecting at-risk populations and lowering community transmission of COVID-19. It plans to explore the potential of the broad-spectrum antiviral immunomodulator in other areas, including COPD, and wider partnering opportunities.

Renaissance Capital expects an initial public offering surge in September; Biomedtracker data show financings for COVID-19 programs fell from Q1 to Q2; Revelation will merge with a special purpose acquisition corporation; Ascendis netted $379.3m in a follow-on offering; and Disc Medicine raised $90m in venture capital.